none
Conditions
Interventions
Healthy volunteers will receive an intravenous injection of the OXTR-PET tracer [11C]OCS5 followed by PET imaging. Blood samples necessary for kinetic analysis will also be collected. To evaluate the
Sponsors
Yamasue Hidenori
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Males and females aged 18 years or older but under 55 years at the time of consent acquisition (2) Healthy individuals with no past medical history (excluding infectious diseases that do not leave sequelae) or current medical conditions (3) Individuals for whom written consent to participate in this study has been obtained from the subject themselves
Exclusion criteria
Exclusion criteria: (1) Individuals diagnosed with a mental disorder or intellectual disability (2) Use of psychotropic medications within the past 6 months (3) Individuals who are pregnant, breastfeeding, or may be pregnant (4) History of hypersensitivity to oxytocin (5) History of epileptic seizures or head trauma with loss of consciousness lasting 5 minutes or longer (6) History of alcohol-related disorders or other substance-related disorders (7) Individuals with serious concomitant diseases (8) Individuals with severe allergies or idiosyncrasies, such as anaphylaxis (9) Individuals unable to obtain consent to use contraception during the study period (10) Individuals who participated in another PET study (involving radiation exposure) within one year prior to obtaining consent (11) Individuals deemed ineligible for this study by the principal investigator (or co-investigator)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Brain Distribution Following Administration of the OXTR-PET Tracer [11C]OCS5 Injection | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety and Pharmacokinetics of the OXTR-PET Tracer [11C]OCS5 Estimated Radiation Exposure Following Administration of the [11C]OCS5 Injection Association between Brain Distribution Following Administration of OXTR-PET Tracer [11C]OCS5 Injection and Individual Differences in Social Behavior and Mental Functioning (Frequency of Nonverbal Information Utilization in the Nonverbal Judgment Task (NVJ), Reaction Time (RT) and Eye Gaze (EG) During the Task, Social Responsiveness Scale (SRS), Autism Quotient (AQ), Stress and Anxiety Assessment (State and Trait Anxiety: STAI), Social Functioning Scale (SFS), Socioeconomic Status (SES) Gender Differences in Brain Distribution Following Administration of the OXTR-PET Tracer [11C]OCS5 Injection Relationship Between Brain Distribution Following Administration of the OXTR-PET Tracer [11C]OCS5 Injection and OXT Blood Concentration Relationship Between Brain Distribution Following Administration of the OXTR-PET Tracer [11C]OCS5 Injection and Brain Function/Structure Indicators Measured by MRI | — |
Contacts
Public ContactMasamichi Yokokura
Hamamatsu University School of Medicine
Outcome results
None listed